Han Xue, Yu Wei
Department of General Practice, Shengli Oilfield Central Hospital, Dongying 257000, Shandong Province, China.
Health Management Center, Shengli Oilfield Central Hospital, Dongying 257000, Shandong Province, China.
World J Gastrointest Surg. 2024 Dec 27;16(12):3729-3736. doi: 10.4240/wjgs.v16.i12.3729.
The 5-year survival rate of patients with advanced gastric cancer remains extremely low (< 15%), whereas the 5-year survival rate of patients with early gastric cancer (EGC) is > 90%. Consequently, strengthening the screening of patients with EGC and precancerous lesions (PCLs) is essential.
To identify the value of serum pepsinogen ratio (PGR) screening for EGC and PCLs in the Shengli Oilfield Central Hospital.
We first selected 385 patients with gastric lesions in the Youcheng area, determining benign lesions, PCLs, and EGC in 135, 123, and 127 cases, respectively, based on endoscopy and case diagnosis. The positive rates of pepsinogen I, pepsinogen II and () in the three groups were detected, and the PGR was calculated. Subsequently, we plotted receiver operating characteristic curves to analyze the screening value of PGR and -positive rates for PCLs and EGC.
PGR expression demonstrated a decreasing trend in patients with benign lesions, PCLs, and EGC successively according to the detection results, whereas the -positive rate was notably increased in patients with PCLs and EGC compared to those with benign lesions. The area under the curves (AUCs) of PGR, , and their combination in differentiating patients with benign lesions from those with PCLs were 0.611, 0.582, and 0.689, respectively; PGR, , and their combination had an AUC of 0.618, 0.502, and 0.618 in distinguishing PCL patients from EGC patients, respectively; the AUCs of PGR, , and their combination in discriminating patients with benign lesions from those with EGC were 0.708, 0.581, and 0.750, respectively.
PGR has great screening potential for patients with EGC and PCLs in the Youcheng area, and the screening efficiency is further improved by combining the -positive rate.
晚期胃癌患者的5年生存率仍然极低(<15%),而早期胃癌(EGC)患者的5年生存率>90%。因此,加强对EGC和癌前病变(PCL)患者的筛查至关重要。
确定胜利油田中心医院血清胃蛋白酶原比值(PGR)筛查EGC和PCL的价值。
我们首先选取了油城地区385例胃部病变患者,根据内镜检查和病例诊断,分别确定135例良性病变、123例PCL和127例EGC。检测三组中胃蛋白酶原I、胃蛋白酶原II和()的阳性率,并计算PGR。随后,绘制受试者工作特征曲线,分析PGR和 -阳性率对PCL和EGC的筛查价值。
根据检测结果,PGR表达在良性病变、PCL和EGC患者中依次呈下降趋势,而PCL和EGC患者的 -阳性率明显高于良性病变患者。PGR、 及其联合检测在区分良性病变患者与PCL患者时的曲线下面积(AUC)分别为0.611、0.582和0.689;PGR、 及其联合检测在区分PCL患者与EGC患者时的AUC分别为0.618、0.502和0.618;PGR、 及其联合检测在区分良性病变患者与EGC患者时的AUC分别为0.708、0.581和0.750。
PGR对油城地区EGC和PCL患者具有较大的筛查潜力,联合 -阳性率可进一步提高筛查效率。